GSK launches once daily, single inhaler-triple therapy for COPD patients
GlaxoSmithKline Pharmaceuticals Limited launched Trelegy Ellipta (fluticasonefuroate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for ChronicObstructive Pulmonary Disease (COPD) patients in a once-daily regime.
The launch follows the product’s approval by the Drugs Controller General of India (DCGI) for use ofTrelegy Ellipta as maintenance treatment to prevent and relieve symptoms associated with ChronicObstructive Pulmonary Disease (COPD) in patients aged 18 and above.
Dr. Rashmi Hegde, Executive Vice President - Medical Affairs, GlaxoSmithKline PharmaceuticalsLimited, said, “We are thrilled to launch Trelegy Ellipta, enabling a greater number of Indian COPDpatients to benefit from this world-leading medicine. This is a significant milestone which exemplifies the GSK ambition for patients. Healthcare professionals in India now have a new once-daily, single inhalertriple therapy for the optimal treatment of their COPD patients.”
Dr. Deepak Talwar, Director & Chair - Pulmonary, Sleep, Allergy & Critical Care Medicine at MetroGroup of Hospitals, said, “COPD is associated with major healthcare and socioeconomic burden onpatients and their caregivers. In appropriate patients, studies show that a combination of three differenttypes of medicines for COPD can effectively improve patients' symptoms and reduce the risk of symptom worsening. Considering 75% COPD patients have four or more co-existing medical conditions, the burden of managing and taking many medications may overwhelm patients, resulting in suboptimal treatment. Single-inhaler triple therapy has the potential role to simplify treatment, improve treatment adherence and patient outcomes.”
In usual clinical care, treatment with single-inhaler Trelegy Ellipta results in significantly more patientswith health status improvements and greater lung benefit, versus multi-inhaler triple therapy, with similarsafety profiles.1
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through itsconsistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers.2,3